Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

[1]  K. Ishii,et al.  Vaccine adjuvants as potential cancer immunotherapeutics , 2016, International immunology.

[2]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[3]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[4]  Alexandria P. Cogdill,et al.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.

[5]  N. Perrimon,et al.  Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch. , 2015, Developmental cell.

[6]  R. Bourgon,et al.  Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display , 2015, Proceedings of the National Academy of Sciences.

[7]  M. Sadelain,et al.  The journey from discoveries in fundamental immunology to cancer immunotherapy. , 2015, Cancer cell.

[8]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[9]  A. Iwasaki,et al.  Control of adaptive immunity by the innate immune system , 2015, Nature Immunology.

[10]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. June,et al.  Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.

[12]  Swapnil Bhatia,et al.  Functional optimization of gene clusters by combinatorial design and assembly , 2014, Nature Biotechnology.

[13]  David Fenyö,et al.  A robust pipeline for rapid production of versatile nanobody repertoires , 2014, Nature Methods.

[14]  A. Snook,et al.  Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. , 2014, Discovery medicine.

[15]  H. Walczak,et al.  Getting TRAIL back on track for cancer therapy , 2014, Cell Death and Differentiation.

[16]  R. Medzhitov,et al.  Stress, inflammation, and defense of homeostasis. , 2014, Molecular cell.

[17]  B. Levine,et al.  Adoptive immunotherapy for cancer or viruses. , 2014, Annual review of immunology.

[18]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[19]  S. McColl,et al.  Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity , 2014, PLoS pathogens.

[20]  D. Teachey,et al.  Toxicity management for patients receiving novel T-cell engaging therapies , 2014, Current opinion in pediatrics.

[21]  A. Gudkov,et al.  A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity , 2014, PloS one.

[22]  David L Porter,et al.  Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.

[23]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[24]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[25]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[26]  Wendell A. Lim,et al.  Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.

[27]  Thomas Gebhardt,et al.  Memory T cell subsets, migration patterns, and tissue residence. , 2013, Annual review of immunology.

[28]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[29]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[30]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[31]  B. Levine,et al.  The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.

[32]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[33]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[34]  S. Rutz,et al.  Regulation and functions of the IL-10 family of cytokines in inflammation and disease. , 2011, Annual review of immunology.

[35]  Wendell A. Lim,et al.  Designing customized cell signalling circuits , 2010, Nature Reviews Molecular Cell Biology.

[36]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[38]  S. Rosenberg,et al.  A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 , 2009, The Journal of Immunology.

[39]  S. Rajkumar,et al.  Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. , 2009, Leukemia research.

[40]  Bruce R. Blazar,et al.  Engineering lymphocyte subsets: tools, trials and tribulations , 2009, Nature Reviews Immunology.

[41]  Sun-Hee Kim,et al.  Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. , 2009, Experimental cell research.

[42]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[43]  C. Hawrylowicz,et al.  Strategies for use of IL‐10 or its antagonists in human disease , 2008, Immunological reviews.

[44]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[45]  M. Sixt,et al.  The microanatomy of T‐cell responses , 2008, Immunological reviews.

[46]  G. Griffiths,et al.  Secretory mechanisms in cell-mediated cytotoxicity. , 2007, Annual review of cell and developmental biology.

[47]  J. Aster,et al.  Structural basis for autoinhibition of Notch , 2007, Nature Structural &Molecular Biology.

[48]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[49]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[51]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[52]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[53]  D. Selkoe,et al.  Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. , 2003, Annual review of neuroscience.

[54]  Mark S. Sundrud,et al.  Genetic Reprogramming of Primary Human T Cells Reveals Functional Plasticity in Th Cell Differentiation , 2003, The Journal of Immunology.

[55]  Raphael Kopan,et al.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. , 2000, Molecular cell.

[56]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[58]  F. Schweisguth,et al.  Indirect evidence for Delta-dependent intracellular processing of Notch in Drosophila embryos , 1998, Current Biology.

[59]  G. Struhl,et al.  Nuclear Access and Action of Notch In Vivo , 1998, Cell.

[60]  H. Prentice,et al.  Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. , 1997, Human gene therapy.

[61]  yang-xin fu,et al.  Immunotherapy and tumor microenvironment. , 2016, Cancer letters.

[62]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[63]  Peter Lipsky,et al.  Cytokines and autoimmunity , 2002, Nature Reviews Immunology.